Dermatology

How Kaiser Permanente Got Biosimilars Into Play

July 29, 2020

Tony Hagen

Article

Biologics are not cheap, and if you can get biosimilars into the hands of patients, you’ve got something going. A strategist describes the step-by-step process that made this possible at Kaiser Permanente.

Webinar: How Biosimilar Rebates Shape Payer Policies, Provider Behavior

July 16, 2020

Tony Hagen

Article

An upcoming webinar from MJH Life Sciences™ will address the payer rebate deals that limit provider choice of biosimilars and complicate clinical pharmacy operations.

New Biologics Are Skewing Exclusivity Periods Longer, Study Says

July 14, 2020

Tony Hagen

Article

The rise of biologics as a class of prescription spending is fueling a trend toward longer exclusivity periods, which ultimately makes access more remote, authors of a new study said.

Looking Back, UK Patients Unhappy With Adalimumab Biosimilar Switch

June 24, 2020

Allison Inserro

Article

The UK results show how challenging switching to a biosimilar can be, according to patient groups.

Revance, Mylan to File Application for Botox Biosimilar

June 1, 2020

Tony Hagen

Article

After some delay, Revance and Mylan have decided to push forward with an FDA application for an onabotulinumtoxinA (Botox) biosimilar.

Humira Sales Grow as Competition Heats Up

May 4, 2020

Tony Hagen

Article

After 17 years on the US market, Humira (adalimumab) proves it can still generate high sales, but competition from biosimilars is growing.

WellDyne Executive Says Formulary Exclusions Are on the Rise

April 23, 2020

Tony Hagen

Article

Jeenal Patel, PharmD, BCGP, a formulary manager for WellDyne, said pharmacy benefit managers (PBMs) and employers are increasingly turning to formulary exclusions to control the rising cost of drugs.

AMCP Posters Demonstrate Value of Biosimilars

April 20, 2020

Skylar Jeremias

Article

Posters presented at the Academy of Managed Care Pharmacy (AMCP) eLearning Days meeting this week from April 20 to 24 reveal important data on biosimilar utilization management, switching, and affordability.

AbbVie Patents Are Costly for Healthcare Consumers

April 11, 2020

Tony Hagen

Article

The Danish medical system saved 82.8% on adalimumab by switching almost all patients from the reference product to biosimilars, but such a benefit for the US healthcare system may not be possible, according to a new study.

BiosanaPharma Reports Positive Phase 1 Results for Omalizumab Biosimilar

April 9, 2020

Tony Hagen

Article

With positive phase 1 study results and a manufacturing process that may cut costs significantly, BiosanaPharma hopes its omalizumab biosimilar candidate will have an edge on the worldwide market.

x